Orforglipron
An oral GLP-1 receptor agonist in development that mimics natural hunger-regulating hormones without injections.
Plain English
Patient-Friendly Explanation
Orforglipron is a new weight management medication that works similarly to injectable GLP-1 drugs but comes in a convenient daily pill form instead of an injection. It helps control appetite and blood sugar by mimicking natural hormones that regulate hunger. This medication is currently being studied in clinical trials and represents an exciting advance in non-injectable weight loss options.
Medical
Clinical Definition
Orforglipron is a non-peptide, oral GLP-1 receptor agonist with a biased signalling profile that preferentially activates cAMP over β-arrestin pathways. Unlike peptide-based GLP-1 agonists, its small-molecule structure confers oral bioavailability without absorption enhancers. Phase 2 clinical trials demonstrated dose-dependent weight loss of up to 14.7% of body weight at 36 weeks, with a safety profile comparable to injectable GLP-1 agents.
Key Insight
Why It Matters
An effective oral GLP-1 agonist could significantly expand access to medical weight loss therapy, particularly for patients with needle phobia or those who prefer pill-based treatment. Dr. Joseph Wang at Accord Medical Clinic monitors emerging pharmacotherapies like orforglipron to offer patients the most current weight management options.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: August 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.